Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment

被引：0

作者：

Kavan, P. ^{[1
]}

Rho, H. ^{[1
]}

Probst, S. ^{[2
]}

Abikhzer, G. ^{[2
]}

Rho, Y. S. ^{[3
]}

Barrera, I ^{[1
]}

机构：

[1] McGill Univ, Segal Canc Ctr, Dept Med Oncol, Montreal, PQ, Canada

[2] Jewish Gen Hosp, Div Nucl Med, Montreal, PQ, Canada

[3] Univ Hawaii, John A Burns Sch Med, Honolulu, HI USA

来源：

JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷

关键词：

neuroendocrine tumor; lutetium; prrt; efficacy; safety;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

H21

引用

页码：193 / 193

页数：1

共 43 条

[21] Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET) [J].

Norman, A. ;

Wee, C. ;

Hobday, T. ;

Kendi, A. ;

Johnson, G. ;

Thorpe, M. ;

Lunn, B. ;

Bach, C. ;

Eiring, R. ;

Halfdanarson, T. .

JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 :192-192

[22] Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues [J].

Ratnayake, G. M. ;

Koffas, A. ;

Theocharopoulos, I ;

Hayes, A. ;

Navalkissoor, S. ;

Gnanasegaran, G. ;

Quigley, A. M. ;

Khoo, B. ;

Mandair, D. ;

Grossman, A. ;

Caplin, M. ;

Alsadik, S. ;

Clark, R. ;

Toumpanakis, C. .

JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 :157-157

[23] Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE [J].

Pretot, Dominique ;

Engel-Bicik, Ivette ;

Kenkel, David ;

Kaufmann, Philipp A. ;

Treyer, Valerie ;

Siebenhuner, Alexander R. .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) :1204-1217

[24] Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity [J].

Vinjamuri, S. ;

Gilbert, T. M. ;

Banks, M. ;

McKane, G. ;

Maltby, P. ;

Poston, G. ;

Weissman, H. ;

Palmer, D. H. ;

Vora, J. ;

Pritchard, D. M. ;

Cuthbertson, D. J. .

BRITISH JOURNAL OF CANCER, 2013, 108 (07) :1440-1448

[25] Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues [J].

Koffas, A. ;

Popat, R. ;

Dimitriou, G. ;

Quigley, A. M. ;

Navalkissoor, S. ;

Caplin, M. ;

Toumpanakis, C. .

NEUROENDOCRINOLOGY, 2016, 103 :81-81

[26] Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs) [J].

Naraev, B. ;

Sharma, N. ;

Engelman, E. ;

Bushnell, D. ;

O'Dorisio, T. ;

Halfdanarson, T. .

NEUROENDOCRINOLOGY, 2012, 96 :50-50

[27] Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients Single-Institution Retrospective Analysis [J].

Katona, Bryson W. ;

Roccaro, Giorgio A. ;

Soulen, Michael C. ;

Yang, Yu-Xiao ;

Bennett, Bonita J. ;

Riff, Brian P. ;

Glynn, Rebecca A. ;

Wild, Damian ;

Nicolas, Guillaume P. ;

Pryma, Daniel A. ;

Teitelbaum, Ursina R. ;

Metz, David C. .

PANCREAS, 2017, 46 (09) :1121-1126

[28] A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China [J].

Ying Wang ;

Depei Wu ;

Xiang Zhang ;

Yuhua Li ;

Yanjie He ;

Qifa Liu ;

Li Xuan ;

Zhenyu Li ;

Kunming Qi ;

Yuqian Sun ;

Shunqing Wang ;

Wenjian Mo ;

Lei Gao ;

Ye Hua ;

Yu Wang ;

Ying Zhang .

BMC Medicine, 22

[29] A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China [J].

Wang, Ying ;

Wu, Depei ;

Zhang, Xiang ;

Li, Yuhua ;

He, Yanjie ;

Liu, Qifa ;

Xuan, Li ;

Li, Zhenyu ;

Qi, Kunming ;

Sun, Yuqian ;

Wang, Shunqing ;

Mo, Wenjian ;

Gao, Lei ;

Hua, Ye ;

Wang, Yu ;

Zhang, Ying .

BMC MEDICINE, 2024, 22 (01)

[30] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS) [J].

Mina M. Swiha ;

Duncan E. K. Sutherland ;

Golmehr Sistani ;

Alireza Khatami ;

Rami M. Abazid ;

Amol Mujoomdar ;

Daniele P. Wiseman ;

Jonathan G. Romsa ;

Robert H. Reid ;

David T. Laidley .

Journal of Cancer Research and Clinical Oncology, 2022, 148 :225-236

← 1 2 3 4 5 →